Joey Bose’s Post

🕛ONE Week Left to Invest in Our Breakthrough Biotech 🖇 invest.cytonics.com Since 2006, Cytonics Corporation has been leading the charge in developing groundbreaking therapies for osteoarthritis. With the steadfast support of our investors, we have successfully raised over $25 million, pushing our innovative CYT-108 therapy into Phase 1 human clinical trials. We invite you to join us on our mission to rid the world of osteoarthritis, once and for all. With 1 week remaining (campaign ends August 25 at 11:59pm PST / August 26th at 2:59am EST), seize the chance to join over 6,000 dedicated shareholders committed to eradicating osteoarthritis, once and for all. This is more than an investment in a breakthrough biotech; it's an investment in the improvement of human health and well-being for generations to come. #biotechnology #drugdevelopment #clinicaltrials #arthritis #regenerativemedicine #investing #crowdfunding

Curie.Bio, a biotech accelerator and investor, said Wednesday it raised $380 million to support its portfolio companies beyond the seed stage, helping advance their drugs into the clinic with Series A rounds. The Cambridge, MA-based firm has 20 therapeutics startups in its portfolio thus far, and one has so far publicly disclosed a Series A. That company, Forward Therapeutics, unveiled a $50 million Series A last November with three oral small molecules in just 18 months. Others are coming up behind it: Astoria Biologica, Decrypt Biomedicine and Differentiated Therapeutics. The firm said it invests in single-asset and platform biotechs, but each drug "must have blockbuster potential," meaning at least $1 billion in peak sales. Christoph Lengaeur, Curie chief scientific officer and co-founder, told me last November the firm sifts through about 1,000 applications a year. "There are some that are good, but you're not really excited about it or it's not for us, or it needs more work, and then there's a lot of shit out there, too, but that's OK. At least, that's how we perceive it. That doesn't mean that's the way it is. We can be wrong." #biotech #vc #venturecapital #accelerator #drugdevelopment #biotechstartups

Ready to join us on our mission to eradicate #osteoarthritis? 🖇 invest.cytonics.com The StartEngine community has come out in full force. 💰 Here are some campaign statistics: ✅ Over $2,600,000 raised from over 1,100 investors ✅ 25% of these have NEVER placed an equity crowdfund investment... we are their first foray into the world of #equitycrowdfunding ✅ 60% are returning Cytonics Corporation shareholders... ❤️ their loyalty is testament to our ability to hit the milestones on our mission! ✅ Over 3,500 prospective investors are following our campaign 🤝 Empowering A Healthier Future Investing in Cytonics is more than a financial decision; it’s a partnership in a transformative health movement. Your contribution is crucial in advancing CYT-108 through clinical trials, pushing it closer to FDA approval and into the hands of those who need it most. Your investment signifies joining a community dedicated to eradicating osteoarthritis and improving health globally. Become a shareholder here: invest.cytonics.com #biotechnology #investing #crowdfunding #arthritis #drugdevelopment

Ready to join us on our mission to eradicate #osteoarthritis? 🖇 invest.cytonics.com The StartEngine community has come out in full force. 💰 Here are some campaign statistics: ✅ Over $2,600,000 raised from over 1,100 investors ✅ 25% of these have NEVER placed an equity crowdfund investment... we are their first foray into the world of #equitycrowdfunding ✅ 60% are returning Cytonics Corporation shareholders... ❤️ their loyalty is testament to our ability to hit the milestones on our mission! ✅ Over 3,500 prospective investors are following our campaign 🤝 Empowering A Healthier Future Investing in Cytonics is more than a financial decision; it’s a partnership in a transformative health movement. Your contribution is crucial in advancing CYT-108 through clinical trials, pushing it closer to FDA approval and into the hands of those who need it most. Your investment signifies joining a community dedicated to eradicating osteoarthritis and improving health globally. Become a shareholder here: invest.cytonics.com #biotechnology #investing #crowdfunding #arthritis #drugdevelopment

Axonis Therapeutics just closed a $115 million Series A round led by Cormorant Asset Management, LP and venBio — its first major financing after subsisting on a string of seed financing deals. Axonis will use the funds to jump into an emerging area of drug development: non-addictive therapies for pain. It’s all part of a new era for Axonis, which was originally founded in 2019 to develop treatments for spinal cord injuries and paralysis. “Pain is just like almost a blank sheet in terms of new therapeutics,” CEO Joanna Stanicka told STAT. “We believe that overall, in terms of who could we help with this treatment in pain space, in epilepsy, in psychiatric neurodevelopmental disorders, would be just incredible.” What do you think of the recent spurt of acute and chronic pain treatments? Comment below. #biotech #startup #lifesciences #pain #chronicpain #drugdevelopment #fundraising #venturecapital #VC #painmanagement #epilepsy #spinalcordinjury

#fundingalert 💼Company: Scorpion Therapeutics 💰Funding: $150 Million ⚡Round: Series C 👥Investors: Frazier Life Sciences , Lightspeed Venture Partners, Willett Advisors and leading #healthcare institutional investors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity Management & Research Company, Boxer Capital, EcoR1 Capital, LLC, Surveyor Capital (a Citadel company), Invus, Wellington Management, Nextech Invest Ltd. (on behalf of one or more funds managed by it), OrbiMed, Logos Capital, Woodline Partners LP, and Casdin Capital, LLC. Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer. Adam Friedman, MD, PhD Albert Cha Read more - https://lnkd.in/gHkJzyni To share your startup story write us on - contact@startuprise.io #Scorpion #fundraising #

𝐎𝐑𝐈 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐫𝐚𝐢𝐬𝐞𝐬 $260𝐌 𝐟𝐮𝐧𝐝 𝐟𝐨𝐫 𝐞𝐚𝐫𝐥𝐲-𝐬𝐭𝐚𝐠𝐞 𝐛𝐢𝐨𝐭𝐞𝐜𝐡𝐬 💸 ORI Capital has raised a $260M #lifesciences fund dedicated to supporting early-stage #biotechnology companies worldwide. The firm, with bases in Hong Kong and the US, aims to invest in companies focused on #diagnostics, #therapeutics, and #drugdelivery for conditions characterized by large unmet needs and high mortality rates. These indications include #cancer, #metabolicdisorders, and #neurodegenerative diseases. Since its inception in 2015, #ORICapital has supported several companies with notable exits, including CG Oncology, which recently had an #IPO raising $380M. #venturecapital #healthtech #biotech #medtech #medicaldevices #executivesearch #recruitment #startups #healthcare #innovation #executivesearch #recruitment #fundraising Read more below ⤵ https://lnkd.in/eNSkHbjv

💲🧧💱 Without sounding too much like Fatboy Slim, we're back once again with a Financial Friday update (Kudos if you get the reference!) Apologies for the delay to this one, I can only blame my lack of technological know how, but as always our marketing guru Rebecca Rich comes to save the day! Some incredible fundraising rounds this week, and an astonishing $1 billion raised by one company alone. Below is an overview of the big deals but watch the video to see more: 💰 Xaira Therapeutics - $1 billion launch 💵 Endeavor BioMedicines - $132.5 million Series C 💴 SynOx Therapeutics - $75 million Series B 💳 Cerevance - $47 million extended Series B 💸 Rubedo Life Sciences - $40 million Series A 💹 PinkDx, Inc. - $40 million launch #financialfridays #venturecapitalist #vcfunding #biotechinvestment

Congratulations to Viola Vogel, Mamta Chabria, and Martin Behe: Tandem Therapeutics has been accepted for the prestigious Wyss Zurich accelerator, to work on unlocking the extracellular matrix, to bring drug efficacy to the next level. A great recognition for a highly promising startup project! https://lnkd.in/eDNXehCg About: Most drug development is focused on targeting cells, overlooking the extracellular matrix that surrounds the cells. Presence of excessive matrix proteins are linked to therapeutic resistance and poor patient outcomes in fibrotic tumors and organ fibrosis. The matrix offers druggable biological real-estate to targets nodes that drive disease progression. Tandem Therapeutics' goal is to precision target this barrier and bring drugs to this disease extracellular matrix thereby enhancing safety and efficacy. Using evolutionarily optimised peptides, we are decoding complex matrix-disease biology to create breakthrough solutions for patients burdened with fibrotic diseases. Tandem Therapeutics is a spin-off of ETH Zürich and has been a winner of all stages of Venture Kick. #VentureKick #SwissStartups

👍🏻👍🏻 𝗣𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗔𝗚𝗘𝗙𝗜, 𝗡𝗼𝘂𝘃𝗲𝗹𝗹𝗲 𝗔𝗴𝗲𝗻𝗰𝗲 𝗘́𝗰𝗼𝗻𝗼𝗺𝗶𝗾𝘂𝗲 𝗲𝘁 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗲̀𝗿𝗲, 𝗮𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝗵𝗼𝘄𝘀 𝘁𝗵𝗮𝘁 𝟮𝟬𝟮𝟰 𝗶𝘀 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘆𝗲𝗮𝗿 𝗳𝗼𝗿 #𝗯𝗶𝗼𝘁𝗲𝗰𝗵. 🚀 Stefan Catsicas and Thomas Heimann, MSc emphasize the importance of understanding the #development phases of biotech companies, and of being discerning about the use of funds raised. They also advise focusing on M&A rather than IPOs. 💡Segments such as #oncology, severe #autoimmune diseases and #genomics are identified as promising, with a particular interest in #microbiome technologies and #longevity. BioAlps - Life Sciences Cluster 🇨🇭 Promotion économique Valais Swiss Biotech Association